



Tuberculosis Country Profile 2021 India

Source: Global tuberculosis report 2021. Geneva: World Health Organization

Disclaimer: Tuberculosis country profiles are generated automatically based on data reported by countries and which are held in WHO's global TB database.

Tuberculosis profile: India

Population 2020: 1 380 million

Estimates of TB burden*, 2020

	Number	(Rate per 100 000 population)
Total TB incidence	2 590 000 (1 780 000-3 550 000)	188 (129-257)
HIV-positive TB incidence	53 000 (36 000-72 000)	3.8 (2.6-5.2)
HIV-negative TB mortality	493 000 (453 000-536 000)	36 (33-39)
HIV-positive TB mortality	11 000 (9 800-12 000)	0.78 (0.71-0.84)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2020	63% (46-92)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2020	20% (14-27)

TB case notifications, 2020

Total new and relapse	1 629 301
- % tested with rapid diagnostics at time of diagnosis	18%
- % with known HIV status	92%
- % pulmonary	71%
- % bacteriologically confirmed [^]	54%
- % children aged 0-14 years	6%
- % women (aged ≥15 years)	36%
- % men (aged ≥15 years)	58%
Total cases notified	1 812 643

TB/HIV care in new and relapse TB patients, 2020

	Number	(%)
Patients with known HIV status who are HIV-positive	30 496	2%
- on antiretroviral therapy	28 931	95%

Drug-resistant TB care**, 2020

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	98%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	96%
Laboratory-confirmed cases - MDR/RR-TB ^{^^}	49 679
Patients started on treatment - MDR/RR-TB ^{^^^}	42 505
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	8 982
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	8 256
MDR/RR-TB cases tested for resistance to any fluoroquinolone	16 354

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2019	84%	2 152 563
Previously treated cases, excluding relapse, registered in 2019	77%	147 159
HIV-positive TB cases registered in 2019	71%	40 031
MDR/RR-TB cases started on second-line treatment in 2018	56%	47 284
XDR-TB cases started on second-line treatment in 2018	48%	2 661

TB preventive treatment, 2020


% of HIV-positive people (newly enrolled in care) on preventive treatment	39%
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	42% (39-46)

TB financing

National TB budget, 2021 (US\$ millions)	544
- Funding source, domestic	66%
- Funding source, international	34%
- unfunded	0%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2020

(Number)




Cases attributable to five risk factors, 2020

(Number)



Total budget

(US\$ millions)



* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone

[^] Calculated for pulmonary cases only

^{^^} Includes cases with unknown previous TB treatment history

^{^^^} Includes patients diagnosed before 2020 and patients who were not laboratory-confirmed